SPECS: Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery

Sponsor
East Lancashire Hospitals NHS Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT04880772
Collaborator
Lancaster University (Other)
40
1
2
22.5
1.8

Study Details

Study Description

Brief Summary

To determine whether exercise and nutrition prehabilitation improves patient outcomes after cancer surgery

Condition or Disease Intervention/Treatment Phase
  • Other: Prehabilitation
N/A

Detailed Description

Preliminary qualitative and quantitative studies suggest that there are benefits (reduced length of stay, improved cardiorespiratory function, reduced postoperative complications and improved quality of life) when prehabilitation is used with the context of cancer care. In 2017 Macmillian Cancer Support developed a strategic 'Evidence and Insight' review on prehabilitation. The outcome of this was to incorporate prehabilitation into routine cancer care and to develop principles and guidance for prehabilitation. This study aims to support this vision and answer some of the questions on the patients who are most likely to benefit from prehabilitation and to quantify some of these benefits by investigating the molecular processes that influence clinical changes

This study primarily seeks to assess the cardiovascular and biological impact of prehabilitation (exercise, nutrition) on patients undergoing hepatobiliary and colorectal cancer surgery. The investigators aim to assess whether there is an improvement in various cardiopulmonary exercise testing (CPET) variables such as maximum oxygen consumption and anaerobic threshold. The investigators also aim to study the inflammatory cytokines associated with cancer and how these markers respond to exercise. These inflammatory markers are thought to play a role in influencing some clinical outcomes such as wound infection and recovery.

The study will also assess secondary outcomes including hospital stay, post operative complications and quality of life. The investigators aim to better understand the biological relationship between anti-inflammatory cytokine levels and the previously mentioned outcomes by measuring and analysing these mediators and performing selected muscle biopsies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
1:1 randomisation to standard care or prehabilitation1:1 randomisation to standard care or prehabilitation
Masking:
Single (Outcomes Assessor)
Masking Description:
CPET clinician/physiologist will be blinded
Primary Purpose:
Treatment
Official Title:
A Single-centre Two-armed Randomised Controlled Trial Comparing Standard Care Alone Versus Exercise and Nutrition Prehabilitation in Elective Patients Undergoing Resectional HPB and Colorectal Cancer Surgery
Actual Study Start Date :
Jul 15, 2021
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Standard care

Standard Care: Surgery school as per ELHT pre-operative guidelines (includes generic pre-operative information, advice and optimisation e.g correction of anaemia)

Experimental: Prehabilitation

Surgery School plus Moderate intensity exercise & Forceval (multivitamin)

Other: Prehabilitation
exercise & multivitamin (nutritional/dietary advice)

Outcome Measures

Primary Outcome Measures

  1. Anaerobic threshold (AT) measured in ml/kg/min and maximum oxygen consumption ( VO2 peak) measured in ml/kg/min [change in baseline AT & VO2 peak at 4 weeks]

    Cardiopulmonary exercise Test (CPET) variables

  2. Inflammatory cytokines [change in baseline cytokines at 4 weeks]

    IL6 IL10 in muscle and blood measured in pg/ml

Secondary Outcome Measures

  1. Clavien-Dindo complication rates [Up to 30 days from the day of operation]

    Grades I-IV

  2. Length of hospital stay measured in days [30 & 90-day mortality]

    Defined as duration of stay from date of operation to discharge

  3. Quality of life measures (Illness Perception Questionnaire) [baseline and within 24 weeks after surgery]

    This questionnaire assesses perceptions on each of the five dimensions(Identity, Cause, Timeline, Consequences, Cure-Control) by asking patients for their own beliefs about their condition. High scores on the identity, consequences, timeline acute/ chronic and cyclical subscales represent strongly held beliefs about the number of symptoms attributed, the negative consequences, and the chronicity and cyclical nature of the illness. High scores on the identity and cure-control and coherence subscales represent positive beliefs about controllability and a personal understanding of the illness.

  4. Hand Grip Strength measured in kg [baseline, immediately after the intervention, within 24 weeks after surgery]

    Measured by digital dynamometer

  5. Quality of life measure (Mental Adjustment to Cancer Scale) [baseline and within 24 weeks after surgery]

    Assessment of participants mental adjustment to a cancer diagnosis. Designed to measure Fighting Spirit (FS), Anxious Preoccupation (AP), Helpless-hopelessness (HH) and Fatalism. This is a 40-item measure of specific psychological (Coping) responses that cancer patients may display in the process of adjusting to the diagnosis and treatment of their disease. A higher score represents higher endorsement of the adjustment response.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18-85

  • Sex: male/female

  • Radiological/tissue cancer diagnosis

  • Curative cancer of the colon, rectum, colorectal liver metastases (CRLM) of 2 or more segments

  • elective surgery (planned a minimum of 3 weeks from the date of first clinic meeting)

  • Access to digital technology(mobile phone, tablet or laptop, home computer) to participate in supervised home exercise

Exclusion Criteria:

Exclusion

  • Palliative disease

  • Haematological malignancy

  • Pregnancy

  • Emergency surgery

  • Physically unable to undergo CPET

  • Part of any other trial with similar interventions unless previously agreed on with all CIs

  • synchronous disease (operation on HPB & colorectal cancers at the same operation)

  • No access to digital technology(smart phone, tablet, laptop or home computer)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Blackburn Hospital Blackburn United Kingdom BB@ 3HH

Sponsors and Collaborators

  • East Lancashire Hospitals NHS Trust
  • Lancaster University

Investigators

  • Principal Investigator: Joel Lambert, Senior Clinical Research Fellow
  • Study Director: Chris Gaffney, Lancaster University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Joel Lambert, Clinical Research Fellow, East Lancashire Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT04880772
Other Study ID Numbers:
  • 290723
First Posted:
May 11, 2021
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Joel Lambert, Clinical Research Fellow, East Lancashire Hospitals NHS Trust
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022